The death-rate ratio of adults aged 70 years and older and children younger than 5 years climbed globally, with the Western Pacific Region experiencing the largest increase.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
While influenza B patients had better short-term outcomes, they experienced higher-than-expected rates of hospitalization, ICU admission, and death.
The group also recommended two vaccine strains for pandemic preparedness, one for the H5N1 2.3.2.1a clade and another targeting the reemerging H5N6 2.3.4.4h clade.
The study involved 68 US children who died from seasonal flu this season.
The Vaccines and Related Biological Products Advisory Committee was scheduled to meet March 13 to select virus strains for the 2025-26 flu vaccine.
The CDC says it does not anticipate posting any more updates on US respiratory disease activity this season.
The CDC says it's now classifying the flu season as high severity for all age-groups for the first time since the 2017-18 season.
Test positivity topped 30%, with steady rises in emergency department visits and hospitalizations.
Median hospital stay was longer in the RSV group than in flu patients.
Oseltamivir recipients had an 18% lower risk of 30-day mortality.
The highest rates of influenza A/B (21%), influenza A (17%), and influenza B (20%) were observed in Asia and Europe.
